Welcome to our dedicated page for MEDICURE news (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on MEDICURE stock.
Medicure Inc. (MCUJF) is a pharmaceutical company focused on developing and commercializing healthcare products in the U.S. market. The company's core business includes the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets. Medicure operates Marley Drug, a pharmacy subsidiary serving all 50 states, Washington D.C., and Puerto Rico, committed to improving access to medications and reducing healthcare costs. Recently, Medicure received Fast Track designation from the FDA for its investigational product MC-1, targeting seizures associated with PNPO deficiency, a rare pediatric disease.
Medicure Inc. (OTC PINK: MCUJF) reported its financial results for the year and quarter ending December 31, 2022. The company achieved a total net revenue of $23.1 million, up from $21.7 million in 2021. For Q4 2022, revenue was $6.3 million, slightly down from $6.8 million in Q4 2021. Key revenue drivers included AGGRASTAT® sales of $11.7 million and ZYPITAMAG® sales of $3.6 million. Adjusted EBITDA increased to $3.3 million from $2.1 million in the prior year. Net income was reported at $1.4 million or $0.13 per share, compared to a loss of $727,000 in 2021. Despite the positive overall financial performance, Medicure made a marketing hold on sodium nitroprusside due to poor commercial viability.
Medicure Inc. (OTC PINK: MCUJF) will announce its 2022 Year End Financial Results via a conference call on April 10, 2023, at 8:30 AM ET. These results will be filed after market close on April 6, 2023. The call will include a Q&A session for stakeholders to address financial performance and operational questions. Medicure specializes in pharmaceutical development for the U.S. cardiovascular market, marketing drugs like AGGRASTAT® and ZYPITAMAG®. The company operates Marley Drug, a pharmacy enhancing healthcare access nationwide.
Medicure announced the resignation of Board member Gerald McDole, effective January 31, 2023. McDole, who served since 2004, was recognized for his valuable contributions. Additionally, the company granted stock options totaling 1,205,000 shares at $1.25 each to directors, officers, and employees, pending approval from the TSX Venture Exchange. Medicure remains focused on its cardiovascular products in the U.S., including AGGRASTAT® and ZYPITAMAG®. The company aims to improve healthcare access through its pharmacy, Marley Drug, which serves various U.S. locations.
Medicure Inc. reported Q3 2022 results with total net revenue of $5.3 million, up from $4.9 million in Q3 2021. Key contributors included AGGRASTAT® ($3.1 million), ZYPITAMAG® ($434,000), and Marley Drug® ($1.8 million). Adjusted EBITDA reached $1.4 million, compared to $282,000 last year. Net income improved to $1.1 million or $0.11 per share, compared to a net loss of $946,000 or $0.09 per share in Q3 2021. The company had unrestricted cash of $4.5 million as of September 30, 2022.
Medicure will present its Q3 2022 financial results via a conference call on November 25, 2022, at 8:30 AM Eastern Time. The financial results will be filed after the market closes on November 24, 2022. Medicure focuses on pharmaceuticals for the U.S. cardiovascular market, marketing AGGRASTAT® and ZYPITAMAG® through its subsidiary, Medicure Pharma Inc. The call will include a Q&A session, and a recording will be available afterward on the company's investor relations page.
FAQ
What is the current stock price of MEDICURE (MCUJF)?
What is the market cap of MEDICURE (MCUJF)?
What is Medicure Inc. focused on?
What are the core products of Medicure Inc.?
What is Marley Drug, Inc.?
What recent designation did Medicure Inc. receive from the FDA?
What is the focus of Medicure's Phase 3 clinical trial?
